This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CAR-T/CEA
Description: TNK/3SBio is a joint venture agreement with Shenyang Sunshine Pharmaceutical to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell technology targeting carcinoembryonic antigen positive cancers.
TNK and 3SBio
In June 2016, Sorrento Therapeutics announced its that subsidiary TNK Therapeutics has entered into a joint venture agreement with Shenyang Sunshine Pharmaceutical (3SBio) to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell (CAR-T) technology targeting carcinoembryonic antigen (CEA) positive cancers. Under the terms of the JVA, 3SBio will make total contributions of $10 million to the joint venture and TNK will grant the joint venture an exclusive license to the CEA CAR-T technology and two additional CARs for cellular therapy for the Greater China market, including Mainland China, Hong Kong and Macau. 3SBio will initially own 51% of the joint venture while TNK will initially hold the remaining 49%.
Partners: Sorrento Therapeutics, Inc.
TNK/3SBio Program News
Additional information available to subscribers only: